Today, I found this preprint on the efficacy of Ivermectin in COVID-19 prophylaxis and treatment. In the context of COVID-19, Ivermectin looks more promising than any other drug I've read results on. The meta-review is partially based on unpublished data, though; it will take time until all the referenced trial results will be published.
10.31219/osf.io/wx3zn
Here is a draft with up-to-date charts:
Meta-analysis of 21 studies
What got my attention, though, is another referenced preprint on post-COVID-19 fatigue treatment with Ivermectin. They couldn't verify if it is CFS because CFS guidelines usually require at least 6 months of persisting symptoms, so the link is currently being investigated. With Ivermectin, they achieved 94% remission in 33 patients. Ivermectin has a good safety profile, so I hope we will see more on this front.
POST-ACUTE OR PROLONGED COVID-19: IVERMECTIN TREATMENT FOR PATIENTS WITH PERSISTENT SYMPTOMS OR POST-ACUTE
10.31219/osf.io/wx3zn
Here is a draft with up-to-date charts:
Meta-analysis of 21 studies
What got my attention, though, is another referenced preprint on post-COVID-19 fatigue treatment with Ivermectin. They couldn't verify if it is CFS because CFS guidelines usually require at least 6 months of persisting symptoms, so the link is currently being investigated. With Ivermectin, they achieved 94% remission in 33 patients. Ivermectin has a good safety profile, so I hope we will see more on this front.
POST-ACUTE OR PROLONGED COVID-19: IVERMECTIN TREATMENT FOR PATIENTS WITH PERSISTENT SYMPTOMS OR POST-ACUTE